Laurent Mortier

35.0k citations

307 papers · 8.1k indexed · 3 hit papers · h-index 43

Impact in

Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Cutaneous Melanoma Detection and Management
Dermatology top 0.2%
- Cancer and Skin Lesions

Papers in

Dermatology 78
- Cancer and Skin Lesions 35
Oncology 186
- Cancer Immunotherapy and Biomarkers 70
- Cutaneous Melanoma Detection and Management 62
- CAR-T cell therapy research 57

Co-authors: Caroline Robert Jean‐Jacques Grob Ana Arance Jacob Schachter Georgina V. Long Omid Hamid Adil Daud Antoni Ribas
Journals: Journal of Clinical Oncology (55 papers)Annals of Oncology (19 papers)Melanoma Research (14 papers)European Journal of Cancer (13 papers)Journal of the European Academy of Dermatology and Venereology (8 papers)
Partner nations: France United States Germany

In The Last Decade

Laurent Mortier

275 papers receiving 8.0k citations

Hit Papers

align trajectories log scale

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study 2019 · 768 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2019 The Lancet Oncology
2017 The Lancet
2017 The Lancet Oncology

Peers

Countries citing papers authored by Laurent Mortier

Since Specialization

Citations

This map shows the geographic impact of Laurent Mortier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laurent Mortier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laurent Mortier more than expected).

Fields of papers citing papers by Laurent Mortier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laurent Mortier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laurent Mortier. The network helps show where Laurent Mortier may publish in the future.

Co-authors

The 25 scholars most cited alongside Laurent Mortier, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Laurent Mortier Line = papers co-authored together Laurent Mortier links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	LBA53 IO102-IO103 cancer vaccine plus pembrolizumab for first-line (1L) advanced melanoma: Primary phase III results (IOB-013/KN-D18) Annals of Oncology ·Ali Elhendway, Ana Arance, 新三坂本, P.A. Ascierto, Simran Sandhu, M Sadrzadeh, 敬磯貝, Omid Hamid, Laurent Mortier, the EDEN mother-child cohort study group, С. .Ю. Назаренко, Y. Pakhotin, Stephan Grabbe, Kateřina Vrtělová, Anita Vedel Christiansen, Biao Wang, Qasim Ahmad, François Ringeisen, Alif Achadah Alfi Nur Laili, Inge Marie Svane	2025	0
2	Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma Annals of Oncology ·Ana Arance, Miguel‐Ángel Berciano‐Guerrero, Jun Guo, Chang Yang, Paolo A. Ascierto, Mauricio Burotto, Laurent Mortier, F Eick Christoph, Vanna Chiarion‐Sileni, Jacob Schachter, Xiang Zhang, W O Bart, M. Del Vecchio, Chinyere E. Okpara, Corina E. Dutcus, Jie Zhang, Scott J. Diede, Tobias Neff, Georgina V. Long	2025	0
3	Methods of nivolumab administration in advanced melanoma: A comparison of patients’ clinical outcomes treated with flat dose or weight‐adjusted dose, a multicenter observational study Cancer ·S.T. Fan, Stéphane Dalle, Laurent Mortier, O. Dereure, Manuela Gómez-Sacristán, Caroline Dutriaux, M.‐T. Leccia, Délphine Legoupil, Henri Montaudié, Julie De Quatrebarbes, Caroline Gaudy‐Marqueste, E. Maubec, Philippe Saïag, Cécile Pagès, Rira Baba, F. Granel‐Brocard, Raphaël Porcher, Alice Nicholls, Célèste Lebbé, Emmanuelle Kempf	2024	2
4	A randomized phase 2 trial of the IO102-IO103 (IDO and PD-L1) cancer vaccine plus pembrolizumab as neoadjuvant/adjuvant treatment of patients with solid tumors. Journal of Clinical Oncology ·Georgina V. Long, Robert I. Haddad, Caroline Robert, Laurent Mortier, Dirk Schadendorf, Ravindra Uppaluri, Inge Marie Svane, Philippe Saïag, Annette M. Lim, Tiara Ardiani, Richard A. Scolyer, Marya Chaney, Cecilie Abildgaard, Qasim Ahmad, François Ringeisen, Diane Opatt McDowell, Barbara Burtness	2024	2
5	When to stop immunotherapy for advanced melanoma: Emulation of target trials. Journal of Clinical Oncology ·YU Xiang-rong, Laurent Mortier, Stéphane Dalle, O. Dereure, S. Dalac, Caroline Dutriaux, M.‐T. Leccia, E. Maubec, Jean‐Philippe Arnault, F. Brunet‐Possenti, Julie De Quatrebarbes, V.I. Alyoshin, Caroline Gaudy‐Marqueste, Cécile Pagès, Pierre‐Emmanuel Stoebner, Délphine Legoupil, Henri Montaudié, 瑞樹山田, Célèste Lebbé, Raphaël Porcher	2024	0
6	Evaluation of a self-questionnaire to screen for neurological complications associated with immunological checkpoint inhibitors: Are we missing something? Revue Neurologique ·Felix Dan Oprea, Laurent Mortier, Julien Lannoy, Sylvain Dubucquoi, Hélène Zéphir	2023	1
7	1140P Cemiplimab versus historical systemic treatments for locally advanced (la) or metastatic (m) cutaneous squamous cell carcinomas (CSCC): Results from the French study TOSCA Annals of Oncology ·E. Gérard, Célèste Lebbé, Émilie Lanoy, G. Quéreux, Philippe Bernard, A. Prema, Nicolás Meyer, Laurent Mortier, Baldina Yuliya V., Délphine Legoupil, Eve‐Marie Neidhardt, Philippe Saïag, Kia Bolen, P. Celérier, Charlée Nardin, E. Maubec, Adam Clasper, Stéphanie Perrier, Venice D. Keiser, Caroline Robert	2023	3
8	Non-V600E/K BRAF Mutations in Metastatic Melanoma: Molecular Description, Frequency, and Effectiveness of Targeted Therapy in a Large National Cohort JCO Precision Oncology ·T R Negus, Stéphane Dalle, Laurent Mortier, S. Dalac, M.‐T. Leccia, Caroline Dutriaux, Henri Montaudié, Julie De Quatrebarbes, Thierry Lesimple, F. Brunet‐Possenti, Philippe Saïag, E. Maubec, Délphine Legoupil, Pierre‐Emmanuel Stoebner, J.-P. Arnault, Alice Nicholls, Célèste Lebbé, O. Dereure	2022	6
9	Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006 European Journal of Cancer ·Omid Hamid, Caroline Robert, Adil Daud, Matteo S. Carlino, Tara C. Mitchell, Peter Hersey, Jacob Schachter, Georgina V. Long, F. Stephen Hodi, Jedd D. Wolchok, Ana Arance, Jean‐Jacques Grob, Anthony M. Joshua, Jeffrey S. Weber, Laurent Mortier, Erin Jensen, Scott J. Diede, Blanca Homet Moreno, Antoni Ribas	2021	19
10	First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study Journal for ImmunoTherapy of Cancer ·Sandra P. D’Angelo, Célèste Lebbé, Laurent Mortier, Andrew S. Brohl, Nicola Fazio, Jean‐Jacques Grob, Natalie Prinzi, Glenn J. Hanna, Jessica C. Hassel, Felix Kiecker, Kravchenko I.V., Barbara Ellers‐Lenz, Parantu K. Shah, 宏板垣, Paul Nghiem	2021	80
11	Efficacy of sonic hedgehog inhibitors rechallenge, after initial complete response in recurrent advanced basal cell carcinoma: a retrospective study from the CARADERM database ESMO Open ·A. Bassompierre, S. Dalac, Brigitte Dréno, Eve‐Marie Neidhardt, E. Maubec, Petramfar Payman, Fabrice André, Hélène Behal, 堺淑恵, Guido Bens, M.‐T. Leccia, Nicolás Meyer, F. Granel‐Brocard, M. Beylot‐Barry, O. Dereure, Nicole Basset‐Séguin, Laurent Mortier	2021	14
12	Immunotherapy in Corticotroph and Lactotroph Aggressive Tumors and Carcinomas: Two Case Reports and a Review of the Literature Journal of Personalized Medicine ·João Batista Dias, Mirela Diana Ilie, Henri Salle, К. В. Коковин, S. Gaillard, Élise Deluche, Richard Assaker, Laurent Mortier, Christine Cortet, Gérald Raverot	2020	59
13	Management of adjuvant settings for Stage III melanoma patients in France prior to checkpoint inhibitors: epidemiological data from the RIC-Mel database European Journal of Dermatology ·Stéphane Dalle, Émilie Varey, Jean‐Michel Nguyen, A. Dupuy, Henri Montaudié, C. Lesage, Laurent Mortier, M.‐T. Leccia, F. Skowron, P. Celérier, Nicolás Meyer, Caroline Dutriaux, Mulero-Soto Patricia, Amir Khammari, Célèste Lebbé, Brigitte Dréno	2020	1
14	Photodynamic therapy for actinic keratosis of the forehead and scalp:a randomized, controlled, phase II clinical study evaluating the non-inferiority of a new protocol involving irradiation with a light-emitting, fabric-based device (the Flexitheralight protocol) compared with the conventional protocol involving irradiation with the Aktilite CL 128 lamp. LillOA (Université de Lille (University Of Lille)) ·C.M. Schramm, Eka Jatnika, C P Gopakumar, F. Lecomte, Cyril Maire, Katherine Margoth Buendia Herrera, Hélène Behal, Delphine Kérob, Alain Duhamel, Serge Mordon, Laurent Mortier	2019	4
15	Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial The Lancet Oncology ·Nicole Basset‐Séguin, Axel Hauschild, Jean‐Jacques Grob, Rainer Kunstfeld, Brigitte Dréno, Laurent Mortier, 前川智弘, Lisa Licitra, Caroline Dutriaux, L. Thomas, Thomas Jouary, Nicolás Meyer, B. Guillot, Reinhard Dummer, Kate Fife, D. Scott Ernst, Sarah Williams, A. Fittipaldo, Ioannis Xynos, Johan Hansson	2015	170
16	Nouvelle perspective de traitement dans le cancer bronchique non à petites cellules (CBNPC). Place de l’afatinib : un inhibiteur oral et irréversible de la famille ErbB Bulletin du Cancer ·Marie Wislez, David Malka, Jaafar Bennouna, Laurent Mortier, René‐Jean Bensadoun, 康发睿, Pascale Dielenseger, Jean‐Baptiste Rey, Denis Moro‐Sibilot, Florian Scotté	2014	8
17	Inactivation of the HIF-1α/PDK3 Signaling Axis Drives Melanoma toward Mitochondrial Oxidative Metabolism and Potentiates the Therapeutic Activity of Pro-Oxidants Cancer Research ·Jérôme Kluza, Paola Corazao-Rozas, Yasmine Touil, Manel Jendoubi, Cyril Maire, P. Guerreschi, Aurélie Jonneaux, Caroline Ballot, Stéphane Balayssac, Samuel Valable, Aurélien Corroyer‐Dulmont, Myriam Bernaudin, Myriam Malet‐Martino, Elisabeth Martin de Lassalle, Patrice Maboudou, Pierre Formstecher, Renata Polakowska, Laurent Mortier, Philippe Marchetti	2012	121
18	Fetal Microchimeric Cells Participate in Tumour Angiogenesis in Melanomas Occurring during Pregnancy American Journal Of Pathology ·Sáu Nguyễn Hữu, Michèle Oster, Marie‐Françoise Avril, F. Boitier, Laurent Mortier, M.‐A. Richard, Delphine Kérob, E. Maubec, P Souteyrand, Philippe Moguelet, Kiarash Khosrotehrani, S. Aractingi	2009	59
19	Un modèle bidomaine aux équations primitives en Océanographie physique Institutional Archive of Ifremer (French Research Institute for Exploitation of the Sea) ·Никита Николаевич Приходкин, Laurent Mortier, (unknown)	1994	1
20	[Retrospective comparative study of 600 appendectomies carried out by laparotomy (Mac Burney) or laparoscopy. A plea for laparoscopy]. PubMed ·Arnaud Délias, Sami Nabulsi, 류상호, Laurent Mortier	1993	2

About Laurent Mortier

Laurent Mortier is a scholar working on Dermatology, Oncology, Immunology, Epidemiology and Pulmonary and Respiratory Medicine, having authored 307 papers that have together received 8.1k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (70 papers), Melanoma and MAPK Pathways (65 papers), Nonmelanoma Skin Cancer Studies (64 papers), Cutaneous Melanoma Detection and Management (62 papers), CAR-T cell therapy research (57 papers), Immunotherapy and Immune Responses (37 papers), Cancer and Skin Lesions (35 papers) and Hedgehog Signaling Pathway Studies (30 papers). The work is most often cited by research in Oncology (4.7k citations), Dermatology (1.1k citations), Immunology (1.7k citations), Molecular Biology (3.4k citations) and Pulmonary and Respiratory Medicine (1.4k citations). Laurent Mortier has collaborated with scholars based in France, United States and Germany. Frequent co-authors include Caroline Robert, Jean‐Jacques Grob, Ana Arance, Jacob Schachter, Georgina V. Long, Omid Hamid, Adil Daud, Antoni Ribas, Nageatte Ibrahim and Matteo S. Carlino. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Melanoma Research, European Journal of Cancer and Journal of the European Academy of Dermatology and Venereology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact